Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

XPhyto: Is Mescaline the Next Big Mood-Modifying Medicine?

It has the potential to be the next frontier in the psychedelics renaissance, and it represents an unprecedented opportunity to innovate a notable advancement in mental health therapy. In anecdotal studies, mescaline has shown promise in treating depression, anxiety, PTSD,...
Marc Davis | April 6, 2021 |

Buzz on the Bullboards: T’is the Season for hot returns, or a lump of coal?

Once the U.S. Thanksgiving is in the rear-view, the mood among North American markets dramatically shifts. Traders must now juggle holidays, gifts, and vacations on one hand, and the end of their...
Jonathon Brown | December 1, 2022 |

Buzz on the Bullboards: Top stories drawing a curtain on the final week of 2022

The market mood is still cautious amid thin holiday trading. US stocks fell for a second day, and Treasury yields rose slightly.
Shoran Devi | December 29, 2022 |

Buzz on the Bullboards: PyroGenesis, Antibe Top All Sectors

The reign of COVID-19 related gains is over on the Stockhouse Bullboards. Instead, the new king comes from the unlikeliest of sectors: Industrials. Of course, it’s not surprising to have a profitable and quickly rising small-cap company in the industrials s...
Omri Wallach | June 17, 2020 |

Aurora Cannabis, Canopy Growth, EXMceuticals - who will be the best turnaround story?

Cannabis shares are not in demand at the moment. About a year ago the growth potential and possibilities of the rediscovered historical medicinal plant seemed to be endless. Today it is different, there is a hangover mood. The hype back then led to a buyer's market. Investors ...
Mario Hose | February 25, 2020 |

Bayer, Siltronic, XPhyto - is it worthwhile to invest now?

Tuesday began with green lights for most listed companies in Germany. The opinions of analysts and company announcements make the stock prices - or they are driven by the mood of economic data. The Ifo Business Climate Index, for example, rose by 2.2 points to 92.6 points in...
Mario Hose | August 25, 2020 |

Evidence Of A Broad Swing In Global Stock Momentum

INSTITUTIONS DRIVE MARKETS Institutions typically lead in the stock market and retail investors follow, which is why equity-based mutual funds and ETFs have seen record outflows in 2019, but the stock market has still gone up. Institutions have been supporting the market...
Chris Ciovacco | December 18, 2019 |

How to Use Price Cycles and Profit as a Swing Trader – SPX, Bonds, Gold, Nat Gas

News does drive certain market events and we understand how certain traders rely on news or interest rates to bias their positions and trades. As technical analysis purists, so to say, we believe the price operates within pure constructs of price rotation theory, trend theory,...
Chris Vermeulen | November 13, 2019 |

Speculators remain skeptical of Veeco Instruments (VECO)

Since March 2009, Veeco Instruments Inc. ’s ( NASDAQ: VECO , Stock Forum ) steep ascent has been underlined by its 10-week and 20-week moving averages. These intermediate-term trendlines have contained all of VECO's weekly closes in the intervening months, ...
Elizabeth Harrow | October 28, 2012 |

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...
Streetwise Reports | December 17, 2019 |
1 2 3 4 5 6 7 8 9 10 ...